Agomab Therapeutics NV, headquartered in Ghent, Belgium, is a clinical-stage biopharmaceutical company dedicated to pioneering treatments for fibro-stenotic and regenerative diseases. Established in 2017, the company leverages its deep understanding of growth factor biology to develop a pipeline of small molecules and antibodies designed to modulate pathways that drive fibrosis and tissue repair. Agomab’s therapeutic strategy focuses on two primary pathways: the Transforming Growth Factor beta (TGF-β) pathway and the Hepatocyte Growth Factor (HGF) pathway. Their lead clinical candidate, AGMB-129, is a gut-restricted, small-molecule inhibitor of ALK5 (TGF-β receptor 1) currently being evaluated for the treatment of fibrostenotic Crohn’s disease. By inhibiting ALK5 locally in the gastrointestinal tract, the company aims to prevent and reverse the fibrotic complications that often lead to surgery in Crohn's patients. In addition to its gastrointestinal programs, Agomab is developing AGMB-447, an inhaled ALK5 inhibitor for Idiopathic Pulmonary Fibrosis (IPF), and AGMB-101, a MET-agonistic antibody designed for regenerative applications in organ failure. The company’s approach combines precision medicinal chemistry with a focus on high unmet medical needs in chronic inflammatory conditions. Led by CEO Tim Knotnerus, Agomab has secured significant backing from prominent life sciences investors and successfully transitioned to a public company on the NASDAQ exchange to fund its expanding clinical trials and research initiatives.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!